Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe, K. 1,2; Knop, F. K. 1; Vilsboll, T. 1; Deacon, C. F. 2; Holst, J. J. 2; Madsbad, S. 3; Krarup, T. 1
Diabetes, Obesity & Metabolism.
12(4):323-333, April 2010.
(Format: HTML, PDF)